The noninvasive ventilation masks market size is projected to reach US$ 3.25 billion by 2031 from US$ 2.05 billion in 2023. The market is expected to register a CAGR of 5.9% during 2023-2031.
Invasive ventilation methods are often avoided in COPD patients to reduce risks of complications such as infections and mechanical lung injuries. Noninvasive ventilation masks are preferred because they provide breathing support without requiring intubation.
A NIV reusable mask is a flexible and contoured device that covers a patient's nose and mouth and connects with a continuous positive airway pressure (CPAP) or bi-level positive airway pressure (BPAP) machine. This device supplies ambient air or a combination of medical oxygen (O2) and air at elevated pressure to the respiratory system for non-invasive positive pressure ventilation (NPPV).
Various products such as PerformaTrak Reusable NIV Mask manufactured by Philips and NIV, non-vented, complete- NIV Face Mask by MSF International are commercially available NIV masks that can be reused during NIV therapy. These reusable NIV masks help healthcare facilities reduce the cost of consumables and provide non-invasive and comfortable ventilation to the patients.
Additionally, Air Liquide Medical Systems, a subsidiary of Air Liquide Healthcare operating in the noninvasive ventilation masks market, launched its ALNEST N1 Silent mask in May 2023. This product is integrated with Quiet Flow leak to ensure an optimal noise level and gent diffusion of the exhaled air. The company’s newly launched Alnest N1 Silent and Alnest N1 are reusable nasal masks with calibrated exhalation orifices.
These NIV masks are designed for home or hospital use by patients (weighing more than 30 kg) who have been prescribed NPPV, such as CPAP or BiPAP therapy. The launch of products with advanced technology, such as Quiet Flow leak, Quiet Flow ventilation port, and innovative headgear, is expected to increase the demand for reusable NIV masks for NIV therapy.
The use of noninvasive ventilation has increased significantly and has become an integral tool in the management of acute and chronic respiratory failure in the home setting. NIV therapy in a homecare setting helps improve survival and quality of life for chronic stable hypercapnia. The patients recovering from acute respiratory failure associated with COPD are required to be evaluated for at least 2-4 weeks after resolution of respiratory acidosis. Thus, they can be provided with NIV at home. Also, stable COPD patients with chronic hypercapnic respiratory failure can benefit from home NIV. These aforementioned benefits drive the demand for NIV masks in home care settings.
The need for personalized NIV masks is widely recognized, and potential strategies are focused on the long-term use of these masks in patients in home settings. In March 2024, researchers from Imperial College London and Sheffield Children's Hospital received funding from children’s charity Action Medical Research and LifeArc, a charitable medical research organization, to develop a fully automated approach to creating customized NIV masks for children. This project will be carried out in partnership with companies such as Photocentric and Polymetrix. Such initiatives by research organizations are likely to bring opportunities for market players to attract new customers.
The growing number of hospitalizations due to increasing incidences of diseases such as asthma, COPD, and other chronic respiratory disorders, and the worldwide presence of hospitals such as Harefield Hospital, SingHealth Group of hospitals, and the Royal Gwent Hospital that provide NIV services also drive the market growth for the segment. The Royal Gwent Hospital, Newport, UK, has been providing NIV retrieval services (NRS) since 2017 with the aim of facilitating optimal management of patients requiring NIV therapy.
United Nation Department of Economic and Social Affairs, World Health Organization, Centers for Diseases Control and Prevention, Food and Drug Administration, and European Center for Disease Prevention and Control are among the primary and secondary sources referred to while preparing the noninvasive ventilation masks market report.
Invasive ventilation methods are often avoided in COPD patients to reduce risks of complications such as infections and mechanical lung injuries. Noninvasive ventilation masks are preferred because they provide breathing support without requiring intubation.
A NIV reusable mask is a flexible and contoured device that covers a patient's nose and mouth and connects with a continuous positive airway pressure (CPAP) or bi-level positive airway pressure (BPAP) machine. This device supplies ambient air or a combination of medical oxygen (O2) and air at elevated pressure to the respiratory system for non-invasive positive pressure ventilation (NPPV).
Various products such as PerformaTrak Reusable NIV Mask manufactured by Philips and NIV, non-vented, complete- NIV Face Mask by MSF International are commercially available NIV masks that can be reused during NIV therapy. These reusable NIV masks help healthcare facilities reduce the cost of consumables and provide non-invasive and comfortable ventilation to the patients.
Additionally, Air Liquide Medical Systems, a subsidiary of Air Liquide Healthcare operating in the noninvasive ventilation masks market, launched its ALNEST N1 Silent mask in May 2023. This product is integrated with Quiet Flow leak to ensure an optimal noise level and gent diffusion of the exhaled air. The company’s newly launched Alnest N1 Silent and Alnest N1 are reusable nasal masks with calibrated exhalation orifices.
These NIV masks are designed for home or hospital use by patients (weighing more than 30 kg) who have been prescribed NPPV, such as CPAP or BiPAP therapy. The launch of products with advanced technology, such as Quiet Flow leak, Quiet Flow ventilation port, and innovative headgear, is expected to increase the demand for reusable NIV masks for NIV therapy.
The use of noninvasive ventilation has increased significantly and has become an integral tool in the management of acute and chronic respiratory failure in the home setting. NIV therapy in a homecare setting helps improve survival and quality of life for chronic stable hypercapnia. The patients recovering from acute respiratory failure associated with COPD are required to be evaluated for at least 2-4 weeks after resolution of respiratory acidosis. Thus, they can be provided with NIV at home. Also, stable COPD patients with chronic hypercapnic respiratory failure can benefit from home NIV. These aforementioned benefits drive the demand for NIV masks in home care settings.
The need for personalized NIV masks is widely recognized, and potential strategies are focused on the long-term use of these masks in patients in home settings. In March 2024, researchers from Imperial College London and Sheffield Children's Hospital received funding from children’s charity Action Medical Research and LifeArc, a charitable medical research organization, to develop a fully automated approach to creating customized NIV masks for children. This project will be carried out in partnership with companies such as Photocentric and Polymetrix. Such initiatives by research organizations are likely to bring opportunities for market players to attract new customers.
End User-Based Insights
Based on end user, the noninvasive ventilation masks market is segmented into hospitals and clinics, homecare, and others. The hospitals and clinics segment held the largest share in the noninvasive ventilation masks market in 2023 and is expected to register the highest CAGR in the market during 2023-2031. There has been an increase in medical costs over the last few decades with developments in healthcare technology. Development in hospital technologies, reforms in health insurance policies, economic growth of various regions, improved reimbursement programs, and various products and services provided are among the major reasons fueling the noninvasive ventilation masks market growth for the hospital and clinics segment.The growing number of hospitalizations due to increasing incidences of diseases such as asthma, COPD, and other chronic respiratory disorders, and the worldwide presence of hospitals such as Harefield Hospital, SingHealth Group of hospitals, and the Royal Gwent Hospital that provide NIV services also drive the market growth for the segment. The Royal Gwent Hospital, Newport, UK, has been providing NIV retrieval services (NRS) since 2017 with the aim of facilitating optimal management of patients requiring NIV therapy.
United Nation Department of Economic and Social Affairs, World Health Organization, Centers for Diseases Control and Prevention, Food and Drug Administration, and European Center for Disease Prevention and Control are among the primary and secondary sources referred to while preparing the noninvasive ventilation masks market report.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. Noninvasive Ventilation Masks Market Landscape
5. Noninvasive Ventilation Masks Market - Key Market Dynamics
6. Noninvasive Ventilation Masks Market - Global Market Analysis
7. Noninvasive Ventilation Masks Market Analysis - by Product
8. Noninvasive Ventilation Masks Market Analysis - by Application
9. Noninvasive Ventilation Masks Market Analysis - by End User
10. Noninvasive Ventilation Masks Market - Geographical Analysis
11. Industry Landscape
12. Company Profiles
13. Appendix
Companies Mentioned
- Hamilton Medical AG
- ResMed Inc
- Fisher & Paykel Healthcare Corp Ltd
- Air Liquide Medical Systems,
- Dragerwerk AG & Co KGaA,
- Intersurgical Ltd
- BMC Medical Co Ltd
- DeVilbiss Healthcare LLC
- Armstrong Medical Ltd
- Koninklijke Philips NV
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 176 |
| Published | October 2024 |
| Forecast Period | 2023 - 2031 |
| Estimated Market Value ( USD | $ 2.05 Billion |
| Forecasted Market Value ( USD | $ 3.25 Billion |
| Compound Annual Growth Rate | 5.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
